Abstract
A previously healthy 41-year- [1] . Older age and incomplete surgical resection typically portend a worse prognosis [2] .
Epidemiology of GBM
Prior radiation therapy is a significant environmental risk factor associated with the development of GBM. Neglia [3] . Interestingly, low-dose ionizing radiation is also a risk factor for the development of malignant glioma, as children treated with 1.5 Gray (Gy) for tinea capitis had an increased incidence of gliomas [4] .
Pathogenesis of GBM
GBM tumours are classified by WHO grading system as grade IV astrocytic tumours. All grades of gliomas tend to occur in the white matter of the cerebral hemispheres [5] . GBM is the highest grade glioma and is typically recognized on histology by large areas of necrosis and microvascular proliferation. In addition, GBM tumours characteristically have the appearance of a pseudopalisading formation of malignant cells surrounding areas of necrosis and haemorrhage [5] . Figure 1B demonstrates [6] . GBM was one of the first neoplasms studied under this program, due in large part to its extremely poor prognosis [7] . One of the initial studies using the data generated from TCGA differentiated GBM [11] , whereas doses greater than 60 Gy do not offer additional survival benefit [12] . [21] . In normal cellular biology, histone proteins help control gene expression by modulating chromatin structure and function. Post-translational modifications of histone tails including acetylation, methylation, ubiquitination and phosphorylation (the histone code), determine how these histone proteins control chromatin remodelling [22] . [23] . HAT inactivity and HDAC over activity have been associated with tumourigenesis [24] . Unlike [25] and improvement in NK cell mediated tumour immunity [26] [27] . Pre-clinical examples of malignancies for which HDAC inhibitors have exhibited a radiosensitizing effect include GBM [28] [29] [30] , head and neck squamous cell cancer [31] , non-small-cell lung cancer [32] , colorectal cancer [33, 34] , prostate cancer [29, 35] , melanoma [36] and metastatic breast cancer [37] .
Standard treatment of GBM

HDAC inhibitors as cancer therapy
HDAC inhibitors belong to a class of agents that target the aberrant epigenetic characteristics of tumour cells. Epigenetic changes refer to alterations that affect gene expression and cellular phenotype without modifying the DNA sequence itself. Histone modification is one such mechanism of alteration, and it plays an important role in tumour formation, progression and resistance to treatment
More specifically, histone acetylation is regulated through the opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs transfer acetyl moieties to lysine residues and HDACs remove the acetyl moieties. HAT activity relaxes chromatin, permitting various transcription factors to interact with DNA, thereby promoting transcription. In contrast, HDAC activity condenses chromatin, preventing access of transcription factors, which leads to transcriptional repression
The exact mechanism by which HDAC inhibitor induced radiosensitization occurs is currently unknown, but it may be due at least in part to the prevention of the DNA damage repair process. HDAC inhibitors prevent DNA double-strand break (DSB) repair, as demonstrated by prolonged expression of phosphorylated H2AX (␥H2AX), a marker for DNA DSBs, following radiation [38] . A variety of HDAC inhibitors have been shown to delay the dispersal of radiation-induced ␥H2AX foci [28-29, 32, 36, 39-40] [36, 41, 45] . [46] . Moreover, in vitro data suggest that HDAC inhibitors may actually protect normal tissue from radiation-induced toxicities. For example, the HDAC inhibitor phenylbutyrate has been shown to improve both DNA repair and cell survival in normal fibroblast cell lines [47] .
HDAC inhibitors and normal tissue radioresponse
To maximize the therapeutic ratio of a radiosensitizing agent, it is important that the drug not enhance the radiation-induced toxicity of normal cells or tissue. It is hypothesized that the aberrant HDAC activity exhibited in tumour cells makes them more susceptible to HDAC inhibitors, and thus, normal tissue toxicity should be minimized. However, there is conflicting pre-clinical data regarding the specificity of HDAC inhibitors for cancer cells compared to normal cells, which should be further clarified given the important clinical safety implications. Several in vitro studies have reported that exposure to HDAC inhibitors does not increase the radiosensitivity of various normal tissue cell lines, including fibroblasts and osteoblasts
In addition, when examined in normal breast and intestinal epithelial cell lines, HDAC inhibitors did not enhance the cellular toxicity induced by a variety of chemotherapeutic DNA damaging agents
In contrast, it has also been reported that some HDAC inhibitors do inhibit the repair of radiation-induced DNA DSBs and increase cellular radiosensitivity of normal cells, specifically lymphocytes [48] and primary skin fibroblasts in vitro [49] . In the study examining lymphocytes, the HDAC inhibitor sodium butyrate inhibited radiation-induced DNA DSBs. However, there was no mention of cell survival, which makes it difficult to assess for a change in radiation sensitivity as measured by cell death [48] [50] . Similarly, an additional study in mice demonstrates that topical phenylbutyrate effectively reduces the severity of radiation-induced oral mucositis, a common and morbid side effect of radiotherapy treatment for head and neck cancers. These findings are similarly associated with a decrease in the expression of TNF-␣ [47] . [59] .
. In the study using fibroblasts, the radiosensitizing effect was demonstrated to vary as a function of the type of HDAC inhibitor used. Of note, fibroblasts treated with VPA did not have an increase in DNA DSBs compared to radiation alone and displayed only a very modest increase in radiation sensitivity [49]. These results indicate that HDAC inhibitors are a complex class of molecules with varied responses to similar assays requiring in-depth study of each drug for its effects on tumour and normal cells. In addition, there is growing in vivo evidence that HDAC inhibitors can actually protect normal tissue from radiationinduced side effects. When applied topically to mice, HDAC inhibitors such as phenylbutyrate, trichostatin A and VPA provide protection against numerous well-defined toxicities of radiation therapy, including cutaneous radiation syndrome, long-term skin fibrosis and radiation-induced malignancies [50]. These observations are correlated at a molecular level with inhibition of pro-inflammatory cytokines such as tumour necrosis factor (TNF)-␣ and transforming growth factor (TGF)-␤, which may be one of the mechanisms by which HDAC inhibitors protect normal tissue
Therapies with the potential to mitigate the incidence and severity of radiation-induced normal tissue toxicity would have tremendous clinical benefit, as often times it is the normal tissue toxicity that limits the delivery of the radiation dose necessary for tumour control.
Clinical safety of HDAC inhibitors
Despite the favourable toxicity profile, HDAC inhibitors used as monotherapies in solid cancers do not tend to significantly improve outcomes compared to current standard therapies [60] [61] [62] [63] [64] (Fig. 2) [28] . Furthermore, VPA is FDA approved, and it is safely and commonly used for the treatment of epilepsy, bipolar disorder and migraine prophylaxis [67] 
Conclusion
Given the number of active clinical trials combining HDAC inhibitors and ionizing radiation, in addition to the trials involving HDAC inhibitors and chemotherapy or biologic agents, the next few years will be revealing regarding the efficacy and safety of HDAC inhibitors as anticancer agents. 
